Search Results - "Dahl, Erika S."
-
1
Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer
Published in Frontiers in oncology (29-11-2017)“…The ataxia-telangiectasia mutated (ATM) protein kinase has been extensively studied for its role in the DNA damage response and its association with the…”
Get full text
Journal Article -
2
ATM inhibition drives metabolic adaptation via induction of macropinocytosis
Published in The Journal of cell biology (02-01-2023)“…Macropinocytosis is a nonspecific endocytic process that may enhance cancer cell survival under nutrient-poor conditions. Ataxia-Telangiectasia mutated (ATM)…”
Get full text
Journal Article -
3
ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells
Published in Heliyon (01-09-2020)“…While therapies targeting deficiencies in the homologous recombination (HR) pathway are emerging as the standard treatment for high grade serous ovarian cancer…”
Get full text
Journal Article -
4
DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A
Published in The Journal of cell biology (02-08-2021)“…Oncogene-induced senescence (OIS) is a stable cell cycle arrest that occurs in normal cells upon oncogene activation. Cells undergoing OIS express a wide…”
Get full text
Journal Article -
5
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer
Published in Molecular cancer research (01-08-2019)“…Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal…”
Get full text
Journal Article -
6
Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers
Published in Cellular and molecular bioengineering (01-10-2020)“…Introduction Bacteria and cancer cells share a common trait—both possess an electronegative surface that distinguishes them from healthy mammalian…”
Get full text
Journal Article -
7
Abstract GMM-022: IDH1 IS A PRO-SENESCENT THERAPY IN HIGH-GRADE SEROUS OVARIAN CANCER
Published in Clinical cancer research (15-11-2019)“…Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and fatal…”
Get full text
Journal Article -
8
Abstract A38: ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells
Published in Clinical cancer research (01-07-2020)“…Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy in the USA. While therapies such as inhibitors against poly (ADP-Ribose) polymerase…”
Get full text
Journal Article -
9
Abstract A35: Targeting the IDH1-mediated metabolic-epigenetic axis in cyclin E-high ovarian cancer
Published in Clinical cancer research (01-07-2020)“…Cyclin E is an oncogene that is overexpressed in approximately 20% of high-grade serous ovarian carcinomas (HGSOC) and is associated with worse survival and…”
Get full text
Journal Article -
10
Abstract 1378: Targeting the metabolic-epigenetic axis to sensitize HR-proficient ovarian cancer to PARP inhibitors
Published in Cancer research (Chicago, Ill.) (15-08-2020)“…Overexpression of the oncogene cyclin E1 is considered one of the initiating factors in fallopian tube transformation and ovarian tumorigenesis. Patients with…”
Get full text
Journal Article -
11
Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer
Published in Molecular cancer research (20-05-2019)“…Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal…”
Get full text
Journal Article